Overall survival (OS) and metastasis-free survival (MFS) by depth of prostate-specific antigen (PSA) decline in the phase III PROSPER trial of men with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with enzalutamide (ENZA).

Maha Hussain,Cora N. Sternberg,Eleni Efstathiou,Karim Fizazi,Qi Shen,Xun Lin,Jennifer Sugg,Joyce Steinberg,Bettina Noerby,Ugo De Giorgi,Neal D. Shore,Fred Saad

Overall survival (OS) and metastasis-free survival (MFS) by depth of prostate-specific antigen (PSA) decline in the phase III PROSPER trial of men with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with enzalutamide (ENZA).

2021

Maha Hussain
Cora N. Sternberg
Eleni Efstathiou
Karim Fizazi
Qi Shen
Xun Lin
Jennifer Sugg
Joyce Steinberg
Bettina Noerby
Ugo De Giorgi
Neal D. Shore
Fred Saad

94Background: The PROSPER trial demonstrated prolonged MFS and OS for men with nmCRPC and rapidly rising PSA treated with ENZA vs placebo, both in combination with androgen deprivation therapy (ADT...

Keywords:

Prostate cancer
overall survival
Oncology
Placebo
castration resistant
Prostate-specific antigen
Internal medicine
metastasis free survival
Androgen deprivation therapy
Enzalutamide
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations